

Gene therapies are transforming the way we treat thousands of diseases by addressing the underlying cause of genetic disease, providing potential lifelong benefits for patients who currently depend on frequent medications, surgeries, and comprehensive multidisciplinary care for disease management.

Despite the promise, our healthcare system has not kept pace with the science, threatening patient access to these transformative therapies.

The Institute for Gene Therapies brings together innovators and patients, business leaders and academics to advocate for a modernized policy framework that reflects medical advances, creating a new reality for patients.

### CORPORATE ADVISORY COUNCIL

The members of our Corporate Advisory Council provide collective input on IGT's priorities and engagement activities.



### PATIENT ADVOCACY ADVISORY COUNCIL

IGT works with advocacy organizations focused on improving patient access & outcomes.



- **Khrystal Davis**, Rare Disease Advocate, Mother of son w/SMA, Founder of Texas Rare Alliance
- **Jenn McNary**, Patient Advocate & Consultant, Founder, **One Rare**
- **Jennifer Handt**, Duchenne Parent-Advocate and Founder, **Charlie's Cure**
- **Lauren Holder**, Huntington's Disease Patient Advocate and Producer/Host of **Help 4 HD Live Podcast**
- **Rolf Benirschke**, Survivor and Patient Advocate Crohn's Disease, Ulcerative Colitis, Colorectal & Bladder Cancer
- **Frankie Bjorklund**, Mother and Angelman Syndrome Patient Advocate

### SCIENTIFIC, ACADEMIC & MEDICAL ADVISORY COUNCIL

IGT collaborates with members of the scientific, medical & academic communities with a special interest in gene therapy.

- **Vivian G. Cheung**, MD, Life Sciences Institute, Department of Pediatrics, University of Michigan



[LEARN MORE AT GENE-THERAPIES.ORG](http://GENE-THERAPIES.ORG)